These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38632203)

  • 21. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
    Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Huo S; Del Tejo V; Du EX; Yang X; Betts KA; Choueiri TK; McGregor B
    Clin Drug Investig; 2022 Jul; 42(7):611-622. PubMed ID: 35696045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
    Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K
    Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
    Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
    Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
    Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
    Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
    Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
    Betts KA; Gao S; Ray S; Schoenfeld AJ
    Future Oncol; 2024 Apr; 20(13):851-862. PubMed ID: 38240151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carroll BT; Theuner J; Li S; Fu P; Kirkwood JM
    JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
    Numakura K; Sekine Y; Osawa T; Naito S; Tokairin O; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Yamamoto R; Nara T; Saito M; Narita S; Akashi H; Tsuchiya N; Shinohara N; Habuchi T
    Int J Clin Oncol; 2024 Jul; 29(7):1019-1026. PubMed ID: 38797782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
    Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
    Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse Events Induced by Nivolumab Plus Ipilimumab
    Kamat S; Patel J; Brown BR; Vyas A
    Cancer Invest; 2022 Oct; 40(9):777-788. PubMed ID: 35916661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
    Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
    Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
    ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
    Xing P; Zhang F; Wang G; Xu Y; Li C; Wang S; Guo Y; Cai S; Wang Y; Li J
    J Immunother Cancer; 2019 Dec; 7(1):341. PubMed ID: 31801636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
    Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
    Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
    Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
    Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
    Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors.
    Kato R; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109443. PubMed ID: 36403521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
    Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
    J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.